Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.

@article{Kelley2009ClinicalSO,
  title={Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.},
  author={Todd W Kelley and Rachid Baz and Mohamad Hussein and Matthew T. Karafa and James R Cook},
  journal={Human pathology},
  year={2009},
  volume={40 3},
  pages={
          405-12
        }
}
Prior studies of myeloma treated with conventional chemotherapy or autologous stem cell transplantation have shown immunohistochemistry for cyclin D1, fibroblast growth factor receptor 3, and p53 to be prognostically significant. The clinical significance of these phenotypic abnormalities in thalidomide-based regimens is currently unknown. We examined the clinical significance of immunohistochemistry for cyclin D1, fibroblast growth factor receptor 3, p53, and cyclin D3 in 94 patients treated… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-6 OF 6 CITATIONS

Similar Papers

Loading similar papers…